蛋白琥珀酸铁口服溶液治疗妊娠期缺铁性贫血疗效研究

Clinical research of iron protein succinate on treatment of pregnant iron deficiency anemia

目的探讨蛋白琥珀酸铁口服溶液治疗妊娠期缺铁性贫血(IDA)的有效性及安全性。方法在2016年于四川、广东、山东、江苏4省选择5家具备资质的三级甲等医院,随机抽取妊娠24~28周、常规产检诊断为IDA的孕妇287例,分为两组:对照组144例(采用多糖铁复合物治疗),研究组143例(采用蛋白琥珀酸铁口服溶液治疗)。治疗2周和4周后检测并记录各项疗效指标及不良反应。结果研究组治疗后2周和4周的血红蛋白改善率分别为31.43%和15.89%,分别高于对照组的7.19%和3.05%(P<0.05);研究组治疗后2周和4周的血红蛋白水平也均高于多对照组(P<0.05)。对于血清铁蛋白和转铁蛋白饱和度的改善效果,两组差异无统计学意义(P>0.05)。两组不良反应发生率比较差异无统计学意(P>0.05)。结论蛋白琥珀酸铁口服溶液不良反应少、易吸收、口感佳,对妊娠期缺铁性贫血具有较好的治疗效果。

ObjectiveTo evaluate the efficacy and safety of proteinsuccinic iron oral liquid on treatment of irondeficiency anemia in pregnant women by using polysaccharide iron complex as a control drug.MethodsA total of 28724-28 weeks pregnant women that were diagnosed of IDA were randomly selected from six qualified Grade Ⅲ Ahospitals in Sichuan Province,Shaanxi Province,Guangdong Province,Shandong Province,and Jiangsu Province in2016. 144 cases were randomly Assigned in the control group and 143 cases in the test group. After 2 weeks and 4 weeksof treatment,various efficacy and safety indicators were detected and recorded.ResultsThe improvement rate ofhemoglobin at 2 weeks and 4 weeks after treatment in the study group were 31.43% and 15.89%,respectively,which werehigher than 7.19% and 3.05% of the control group(P<0.05). The hemoglobin levels of the study group were also higherthan the polysaccharide iron complex at 2 and 4 weeks after treatment(P<0.05). There was no significant differencebetween the two groups in the improvement of serum ferritin and transferrin saturation(P>0.05). There was no significantdifference in the incidence of adverse reactions between the two groups(P>0.05).ConclusionProtein iron succinateoral solution has less adverse reactions,easy absorption,good taste,and has a good therapeutic effect on pregnant irondeficiency anemia.